All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
BEIJING – Hightide Therapeutics Inc., of Shenzhen, China, and Rockville, Md., said it finished the enrollment in phase IIa trials for its lead asset, HTD-1801, which is a potential first-in-class new molecular entity for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH).